Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BLK-IN-1
CAS:<p>BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.</p>Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Formula:C22H21N5O3Color and Shape:SolidMolecular weight:403.43EGFR-IN-60
CAS:<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>Formula:C28H28Cl2N6OColor and Shape:SolidMolecular weight:535.47ZT55
CAS:<p>ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.</p>Formula:C17H16N2O3Color and Shape:SolidMolecular weight:296.32VEGFR-2-IN-24
CAS:<p>VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.</p>Formula:C28H23N3O6SColor and Shape:SolidMolecular weight:529.56FGFR4-IN-11
CAS:<p>FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.</p>Formula:C29H29N5O5Color and Shape:SolidMolecular weight:527.57c-Met-IN-14
CAS:<p>c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.</p>Formula:C34H38ClFN4O7SColor and Shape:SolidMolecular weight:701.2EGFR-IN-26
CAS:<p>EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.</p>Formula:C29H34N6O3Color and Shape:SolidMolecular weight:514.62TRK/ALK-IN-1
<p>TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.</p>Formula:C31H35ClF2N8O2SColor and Shape:SolidMolecular weight:657.18FGFR3-IN-1
CAS:<p>FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).</p>Formula:C28H39N9O3SColor and Shape:SolidMolecular weight:581.73EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Formula:C22H15N5O2SColor and Shape:SolidMolecular weight:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Formula:C13H11N3O2Color and Shape:SolidMolecular weight:241.25Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Formula:C9H9NO3Color and Shape:SolidMolecular weight:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Formula:C20H13Cl2FN4OColor and Shape:SolidMolecular weight:415.25EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Formula:C25H25Cl2N7O2Color and Shape:SolidMolecular weight:526.42CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Formula:C27H35ClN6O5SPurity:98%Color and Shape:SolidMolecular weight:591.12MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Formula:C21H23N3OSPurity:98%Color and Shape:SolidMolecular weight:365.49HIV-IN-6
CAS:<p>HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.</p>Formula:C20H16N4O3SPurity:97.12%Color and Shape:SolidMolecular weight:392.43Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Formula:C20H25NO5Color and Shape:SolidMolecular weight:359.42TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Formula:C29H31F3N8OPurity:98%Color and Shape:SolidMolecular weight:564.6EGFR-IN-88
CAS:<p>EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis</p>Formula:C22H18Cl2N4O2SPurity:98%Color and Shape:SolidMolecular weight:473.37BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Formula:C24H27FN4O4Color and Shape:SolidMolecular weight:454.49FGFR4-IN-5
CAS:<p>FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.</p>Formula:C23H23Cl2N5O5Color and Shape:SolidMolecular weight:520.37DPPY
CAS:<p>DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.</p>Formula:C25H26ClN7O3Color and Shape:SolidMolecular weight:507.97PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Formula:C27H39N9OColor and Shape:SolidMolecular weight:505.66KRC-108
CAS:<p>KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.</p>Formula:C20H20N6OColor and Shape:SolidMolecular weight:360.41YF-452
CAS:<p>YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.</p>Formula:C24H26BrN3OPurity:98%Color and Shape:SolidMolecular weight:452.39Multi-kinase-IN-3
CAS:<p>Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).</p>Formula:C33H33N5O3Color and Shape:SolidMolecular weight:547.65VEGFR-2-IN-30
<p>VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.</p>Formula:C28H23ClN6O4S2Color and Shape:SolidMolecular weight:607.1VEGFR-2-IN-21
CAS:<p>VEGFR-2-IN-21 is a potent inhibitor of VEGFR-2 (IC50: 0.10 μM) and exhibits anticancer effects.</p>Formula:C28H24ClN7O3SColor and Shape:SolidMolecular weight:574.05VEGFR-2-IN-22
CAS:<p>VEGFR-2-IN-22 blocks VEGFR-2/beta-tubulin, IC50=19.82 nM, induces apoptosis.</p>Formula:C26H24ClFN4O6Color and Shape:SolidMolecular weight:542.94SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formula:C24H26N8O3Color and Shape:SolidMolecular weight:474.52FGFR-IN-7
CAS:<p>FGFR-IN-7: Oral FGFR modulator, crosses blood-brain barrier, neuroprotective, phospholipidosis-resistant, useful for neurodegeneration study.</p>Formula:C16H21ClF2N4O2Color and Shape:SolidMolecular weight:374.81EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Formula:C24H25ClN6O3Color and Shape:SolidMolecular weight:480.95EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4Lck Inhibitor III
CAS:<p>Lck Inhibitor III, a potent inhibitor of Lck, exhibits an IC50 value of 867 nM.</p>Formula:C25H30N6O4Color and Shape:SolidMolecular weight:478.54K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Formula:C15H13F2N7O2S2Purity:99.12%Color and Shape:SolidMolecular weight:425.44EGFR/BRAFV600E-IN-1
CAS:<p>EGFR/BRAFV600E-IN-1 inhibits EGFR (0.08 μM) & BRAFV600E (0.15 μM), affects A-549, MCF-7, Panc-1 & HT-29 (IC50: 0.79-1.3 μM).</p>Formula:C24H24ClN3O3Color and Shape:SolidMolecular weight:437.92PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Formula:C28H23ClF3N7O2Color and Shape:SolidMolecular weight:581.98FAK/aurora kinase-IN-1
CAS:<p>FAK/aurora kinase-IN-1, a dual inhibitor of FAK and aurora kinase, has IC50 values of 6.61 nM and 0.91 nM respectively, and demonstrates anticancer effects (WO2018019252A1; compound 11) [1].</p>Formula:C23H24ClN7O3Color and Shape:SolidMolecular weight:481.93GW694590A
CAS:<p>GW694590A (UNC10112731) functions as a MYC protein stabilizer that enhances the levels of endogenous MYC protein. It also acts on receptor tyrosine kinases, inhibiting DDR2, KIT, and PDGFRα by 81%, 68%, and 67% at a concentration of 1 μM, respectively. As a protein kinase inhibitor, GW694590A affects both ATP-dependent and ATP-independent luciferases, potentially influencing the Fluc reporter gene [1].</p>Formula:C22H19N5O4Color and Shape:SolidMolecular weight:417.42EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Formula:C27H27F3N6O2SColor and Shape:SolidMolecular weight:556.6Rac-ZINC4085554
CAS:<p>Compound 1T-0219 (SC) is a blocker of AKT1-FAK interaction reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620</p>Formula:C20H19N3O7Purity:90%Color and Shape:SolidMolecular weight:413.38VI 16832
CAS:<p>VI 16832 is a broad-spectrum Type I kinase inhibitor used to quantify relative kinase abundance and study signaling across SILAC-encoded cancer cell lines.</p>Formula:C22H25N5O2Purity:98%Color and Shape:SolidMolecular weight:391.47EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Formula:C26H33N9O3SPurity:98.52% - 99.79%Color and Shape:SolidMolecular weight:551.66Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Purity:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidENMD-1198
CAS:<p>ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.</p>Formula:C20H25NO2Purity:98%Color and Shape:SolidMolecular weight:311.42WDR5-IN-4
CAS:<p>WIN site inhibitor 1 is a WIN site of chromatin-associated WD repeat-containing protein 5 (WDR5) inhibitor (Kd: 0.1 nM), with anti-cancer activity.</p>Formula:C25H22Cl2FN5OPurity:98%Color and Shape:SolidMolecular weight:498.38Glufanide disodium
CAS:<p>Glufanide disodium is an immunomodulator.</p>Formula:C16H17N3O5Na2Color and Shape:SolidMolecular weight:377.3SB-220025 trihydrochloride
CAS:<p>SB-220025 trihydrochloride is an effective and specific human p38 mitogen-activated protein kinase inhibitor.</p>Formula:C18H22Cl3FN6Purity:98%Color and Shape:SolidMolecular weight:447.77WB-308
CAS:<p>WB-308 is an EGFR inhibitor that acts by decreasing NSCLC cell proliferation and colony formation and causing G2/M arrest and apoptosis.</p>Formula:C19H17FN2OPurity:98%Color and Shape:SolidMolecular weight:308.35Tyrphostin AG 568
CAS:<p>Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.</p>Formula:C13H9N5O2Purity:98%Color and Shape:SolidMolecular weight:267.24KRCA-0713
CAS:<p>KRCA-0713 is a ALK inhibitor.</p>Formula:C26H32ClN5O3SPurity:98%Color and Shape:SolidMolecular weight:530.08BGB659
CAS:<p>BGB659 is effective inhibitor of RAF.</p>Formula:C29H29F3N4O3Purity:98%Color and Shape:SolidMolecular weight:538.564-DAMP
CAS:<p>4-DAMP (4-DAMP methiodide) is a selective muscarinic M1 and M3 subtype receptor antagonist used in the study of allergic rhinitis and cardiovascular disease.</p>Formula:C21H26INO2Purity:98%Color and Shape:SolidMolecular weight:451.34PF-06465469
CAS:<p>PF-06465469 is a covalent ITK inhibitor(IC50: 2 nM).</p>Formula:C30H33N7O2Purity:98%Color and Shape:SolidMolecular weight:523.63EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Formula:C16H16BrN3OPurity:98% - 99.6%Color and Shape:SolidMolecular weight:346.22JG26
CAS:<p>JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively,</p>Formula:C19H22Br2N4O6SPurity:98.79% - 99.08%Color and Shape:SolidMolecular weight:594.27DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Formula:C21H23N7OPurity:98%Color and Shape:SolidMolecular weight:389.45E-4177
CAS:<p>E-4177 is an angiotensin II type 1 receptor (AT1R) antagonist and can be used to study cardiovascular diseases.</p>Formula:C24H21N3O2Purity:98.67% - 99.57%Color and Shape:SolidMolecular weight:383.44MG-262
CAS:<p>MG-262 is a reversible proteasome inhibitor with multiple biological activities [1] [2] [3].</p>Formula:C25H42BN3O6Color and Shape:SolidMolecular weight:491.43BI1002494
CAS:<p>BI1002494 is an effective and selective Syk inhibitor.</p>Formula:C23H25N3O5Purity:98%Color and Shape:SolidMolecular weight:423.46Burixafor hydrobromide
CAS:<p>Burixafor hydrobromide is an oral CXCR4 blocker with anti-angiogenic properties, potentially treating choroid neovascularization.</p>Formula:C27H52BrN8O3PPurity:98%Color and Shape:SolidMolecular weight:647.644Lorpucitinib
CAS:<p>Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.</p>Formula:C22H28N6O2Purity:99.72%Color and Shape:SolidMolecular weight:408.5ZK-261991
CAS:<p>ZK-261991 is an orally active inhibitor of VEGFR tyrosine kinase(IC50 of 5 nM, VEGFR2).</p>Formula:C24H25N7O2Purity:98%Color and Shape:SolidMolecular weight:443.5CAY10583
CAS:<p>CAY10583 is a selective BLT2 agonist that increases TGF-β1 and bFGF, promotes keratinocyte migration, accelerates wound healing in diabetic mice.</p>Formula:C25H25NO3Purity:98%Color and Shape:SolidMolecular weight:387.47JAK3-IN-1
CAS:<p>JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.</p>Formula:C26H30ClN7O2Color and Shape:SolidMolecular weight:508.02Rogaratinib
CAS:<p>Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR).</p>Formula:C23H26N6O3SPurity:99.54%Color and Shape:SolidMolecular weight:466.56FGFR2-IN-2
CAS:<p>FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.</p>Formula:C23H22N4OPurity:98.09%Color and Shape:SolidMolecular weight:370.45Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Formula:C19H18BrClN6OPurity:97.03%Color and Shape:SolidMolecular weight:461.74VEGFR-2-IN-6
CAS:<p>VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis [1].</p>Formula:C20H21N7O2SPurity:99.01%Color and Shape:SolidMolecular weight:423.49Tafetinib
CAS:<p>Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.</p>Formula:C24H29FN4O2Purity:96.23%Color and Shape:SolidMolecular weight:424.51CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Formula:C25H24ClN7O2Purity:99.66%Color and Shape:SolidMolecular weight:489.96BMS-605541
CAS:<p>BMS-605541 is a potent and selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity(Ki=49 nM).</p>Formula:C19H17F2N5OSPurity:98.07%Color and Shape:SolidMolecular weight:401.43WDR5-0102
CAS:<p>WDR5-0102 inhibits WDR5-MLL1 (Kd=4 μM), blocks MLL1 HMT activity, but doesn't affect SETD7 and 6 other HMTs.</p>Formula:C18H19ClN4O3Purity:98.03%Color and Shape:SolidMolecular weight:374.82Cloperastine fendizoate
CAS:<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Formula:C40H38ClNO5Purity:99.97%Color and Shape:SolidMolecular weight:648.19A-935142
CAS:<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Formula:C18H19F3N2O2Purity:98.97% - 99.91%Color and Shape:SolidMolecular weight:352.35PKI-166
CAS:<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Formula:C20H18N4OPurity:99.2%Color and Shape:SolidMolecular weight:330.38HIF-2α-IN-3
CAS:<p>HIF-2α-IN-3 is an allosteric inhibitor of HIF-2α (IC50: 0.4 μM; KD: 1.1 μM) with anticancer activity.</p>Formula:C12H6ClN5O5Purity:98.11%Color and Shape:SolidMolecular weight:335.66STS-E412
CAS:<p>STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.</p>Formula:C15H15ClN4O2Purity:99.01%Color and Shape:SolidMolecular weight:318.76A 419259 trihydrochloride
CAS:<p>A 419259 trihydrochloride (RK 20449 trihydrochloride) is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).</p>Formula:C29H37Cl3N6OPurity:99.75% - 99.96%Color and Shape:SolidMolecular weight:592SI-2 hydrochloride
CAS:<p>SI-2 hydrochloride, an SRC-3 inhibitor, induces breast cancer cell death (IC50: 3-20 nM) with good oral bioavailability.</p>Formula:C15H16ClN5Purity:98.6%Color and Shape:SolidMolecular weight:301.77H-9 dihydrochloride
CAS:<p>H-9 dihydrochloride: Strong PKA inhibitor, curbs 5-HT response and EGF signaling, affects pharyngeal function.</p>Formula:C11H15Cl2N3O2SPurity:97.3%Color and Shape:SolidMolecular weight:324.23CTA 056
CAS:<p>CTA 056 is an ITK inhibitor that inhibits the growth of MOLT-4 xenograft tumors in mice and can be used to study autoimmune disorders.</p>Formula:C35H34N6OPurity:97.22% - 97.76%Color and Shape:SolidMolecular weight:554.68MBM-55
CAS:<p>MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM.</p>Formula:C28H27FN6O2Purity:99.83%Color and Shape:SolidMolecular weight:498.55Tyrphostin A25
CAS:<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Formula:C10H6N2O3Purity:98.76%Color and Shape:Yellow Green Powder /Off-White SolidMolecular weight:202.17JNJ-49095397
CAS:<p>JNJ-49095397 (RV568) is a p38 MAPK-α and p38 MAPK-γ kinase inhibitor for the study of respiratory syncytial virus infection.</p>Formula:C34H36N6O4Purity:98.33% - 99.04%Color and Shape:SolidMolecular weight:592.69TC-S 7009
CAS:<p>TC-S 7009: Strong HIF-2α inhibitor (Kd 81 nM), weak for HIF-1α; disrupts dimerization & gene expression.</p>Formula:C12H6ClFN4O3Purity:99.46% - 99.71%Color and Shape:SolidMolecular weight:308.65EGFR-IN-11
CAS:<p>EGFR-IN-11 selectively blocks EGFR-tyrosine kinase and promotes apoptosis; targets EGFRL858R/T790M/C797S, IC50=18 nM; halts cell cycle at G0/G1.</p>Formula:C29H35N9O2SPurity:99.93%Color and Shape:SolidMolecular weight:573.71NX-2127
CAS:<p>NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative</p>Formula:C39H45N9O5Purity:99.07%Color and Shape:SolidMolecular weight:719.83P505-15 Acetate
CAS:<p>P505-15 Acetate inhibits spleen tyrosine kinase, reduces immune response and inflammation, and lowers arthritis severity.</p>Formula:C21H27N9O3Purity:99.99%Color and Shape:SolidMolecular weight:453.5Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formula:C29H32Cl2N2O5SPurity:99.51% - 99.83%Color and Shape:SoildMolecular weight:591.55TP0427736 hydrochloride
CAS:<p>TP0427736 hydrochloride is a novel and selective ALK5 inhibitor, capable of inhibiting Smad2/3 phosphorylation in A549 cells.</p>Formula:C14H11ClN4S2Purity:98.99%Color and Shape:SolidMolecular weight:334.85c-Fms-IN-3
CAS:<p>c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.</p>Formula:C23H30N6OPurity:99.87%Color and Shape:SolidMolecular weight:406.52Dasatinib hydrochloride
CAS:<p>Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).</p>Formula:C22H27Cl2N7O2SPurity:99.88% - 99.98%Color and Shape:SolidMolecular weight:524.47PI3K/VEGFR2-IN-1
CAS:<p>PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.</p>Formula:C17H14ClN3OSPurity:98%Color and Shape:SolidMolecular weight:343.83EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Formula:C29H26FN5O3Purity:98%Color and Shape:SolidMolecular weight:511.55BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Formula:C37H42N8O4Color and Shape:SolidMolecular weight:662.78FGFR-IN-4
CAS:<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Formula:C24H21N7O2Color and Shape:SolidMolecular weight:439.47HPK1-IN-2 dihydrochloride
CAS:<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Formula:C19H22Cl2N6OSColor and Shape:SolidMolecular weight:453.39FC 11
CAS:<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Formula:C41H42F3N13O9SColor and Shape:SolidMolecular weight:949.91HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formula:C27H33N7O3Color and Shape:SolidMolecular weight:503.6Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Formula:C26H31ClN6O2Purity:98%Color and Shape:SolidMolecular weight:495.02HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Formula:C31H41N7O4Color and Shape:SolidMolecular weight:575.7HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Formula:C25H26Cl2N6O3Color and Shape:SolidMolecular weight:529.42EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Formula:C28H32F2N6O5Purity:99.08% - 99.38%Color and Shape:SolidMolecular weight:570.59BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Formula:C20H22Cl2N6OColor and Shape:SolidMolecular weight:433.33EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Formula:C19H21N5O3Purity:97.4%Color and Shape:SolidMolecular weight:367.4BPR1J-340
CAS:<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Formula:C29H34N8O3Color and Shape:SolidMolecular weight:542.63CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Formula:C22H25BrF5N5O5SPurity:98%Color and Shape:SolidMolecular weight:646.43JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formula:C22H23BrFN5O2Purity:98%Color and Shape:SolidMolecular weight:488.35FLT3/ITD-IN-5
CAS:<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Formula:C23H25N7O2Color and Shape:SolidMolecular weight:431.49AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Formula:C22H29N7O5Purity:98%Color and Shape:SolidMolecular weight:471.52BCR-ABL-IN-4
CAS:<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Formula:C27H24ClF2N5O4Color and Shape:SolidMolecular weight:555.96HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Formula:C16H8F5NO4SPurity:97.99%Color and Shape:SolidMolecular weight:405.3Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formula:C30H37N7O2Color and Shape:SolidMolecular weight:527.66BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formula:C22H25BrN4O2Purity:99.02%Color and Shape:SolidMolecular weight:457.36TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Formula:C26H17F4N5O4Color and Shape:SolidMolecular weight:539.44CCT365623 hydrochloride
CAS:<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Formula:C18H18ClNO4S3Purity:98%Color and Shape:SolidMolecular weight:443.99CT-721
CAS:<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Formula:C30H29ClN6OPurity:98%Color and Shape:SolidMolecular weight:525.04(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formula:C16H14N2O2Color and Shape:SolidMolecular weight:266.29FLT3-IN-14
CAS:<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Formula:C25H24N6O2SColor and Shape:SolidMolecular weight:472.5610Z-Hymenialdisine
CAS:<p>Pan kinase inhibitor</p>Formula:C11H10BrN5O2Purity:98%Color and Shape:Light Yellow SolidMolecular weight:324.13Henatinib
CAS:<p>Henatinib: orally active multi-kinase inhibitor targeting VEGFR-2, c-kit, PDGFR with antitumor effects.</p>Formula:C25H29FN4O4Color and Shape:SolidMolecular weight:468.52Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Formula:C24H28N6O3SPurity:99.21% - >99.99%Color and Shape:SolidMolecular weight:480.58TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Formula:C26H27Cl2N5O2Purity:98%Color and Shape:SolidMolecular weight:512.43EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97JAK-IN-26
CAS:<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formula:C22H24N6O3Purity:98%Color and Shape:SolidMolecular weight:420.46Larixol
CAS:<p>Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for</p>Formula:C20H34O2Purity:98%Color and Shape:SolidMolecular weight:306.48Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Formula:C17H20N6O4SColor and Shape:SolidMolecular weight:404.45Risvodetinib
CAS:<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Formula:C33H34N8O2Color and Shape:SolidMolecular weight:574.68JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formula:C18H21N4Na2O6PPurity:98%Color and Shape:SolidMolecular weight:466.341ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Formula:C30H35F3N6O3Purity:98%Color and Shape:SolidMolecular weight:584.63EGFR kinase inhibitor 1
CAS:<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Formula:C30H31N7O2Color and Shape:SolidMolecular weight:521.61BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formula:C26H22ClN5O3Color and Shape:SolidMolecular weight:487.94FGFR-IN-8
CAS:<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Formula:C27H31Cl2N9O2Color and Shape:SolidMolecular weight:584.5BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Formula:C26H23N7O2Color and Shape:SolidMolecular weight:465.51CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Formula:C26H29N7O2Purity:99.63%Color and Shape:SolidMolecular weight:471.55MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Formula:C46H54ClFN8O8Color and Shape:SolidMolecular weight:901.42FGFR-IN-2
CAS:<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Formula:C25H30N6O2Color and Shape:SolidMolecular weight:446.54GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formula:C24H26N2O2Color and Shape:SolidMolecular weight:374.48EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Formula:C29H35Cl2N7O5Color and Shape:SolidMolecular weight:632.54FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Formula:C17H21FN6OPurity:98%Color and Shape:SolidMolecular weight:344.39Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Formula:C27H33FN4O7Color and Shape:SolidMolecular weight:544.57Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Formula:C13H19BrN4Purity:99.34%Color and Shape:SolidMolecular weight:311.22PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Formula:C22H21ClN6O2Color and Shape:SolidMolecular weight:436.89JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Formula:C26H30N6OPurity:98%Color and Shape:SolidMolecular weight:442.56Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Purity:95%Color and Shape:LiquidEGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formula:C36H46BrN8O2PColor and Shape:SolidMolecular weight:733.68Atiprimod dimaleate
CAS:<p>Atiprimod Dimaleate is a JAK2 inhibitor.</p>Formula:C30H52N2O8Color and Shape:SolidMolecular weight:568.74BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Formula:C27H34ClN7O3SPurity:98%Color and Shape:SolidMolecular weight:572.12Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formula:C25H26ClFN4O4Purity:99.7%Color and Shape:SolidMolecular weight:500.95TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Formula:C51H66N10O7S2Color and Shape:SolidMolecular weight:995.26SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Formula:C18H19NO5Purity:98%Color and Shape:SolidMolecular weight:329.35Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.56Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formula:C26H29ClN8OColor and Shape:SolidMolecular weight:505.01BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Formula:C21H22Cl2N6OColor and Shape:SolidMolecular weight:445.35UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Formula:C30H44N6OColor and Shape:SolidMolecular weight:504.71DW10075
CAS:<p>DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.</p>Formula:C29H23N5O3Color and Shape:SolidMolecular weight:489.52(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Formula:C24H28N6O3Purity:98%Color and Shape:SolidMolecular weight:448.52MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Formula:C29H23F3N4O2Purity:98%Color and Shape:SolidMolecular weight:516.51BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formula:C16H12BrN5Color and Shape:SolidMolecular weight:354.2EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Formula:C32H28BrF3N6O4SColor and Shape:SolidMolecular weight:729.57SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Formula:C10H18O4Purity:≥98%Color and Shape:SolidMolecular weight:202.25FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Formula:C25H22N4O5Color and Shape:SolidMolecular weight:458.47YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formula:C30H30N4O3Purity:98%Color and Shape:SolidMolecular weight:494.58T338C Src-IN-1
CAS:<p>T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).</p>Formula:C17H20N6O2SPurity:98%Color and Shape:SolidMolecular weight:372.44JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formula:C25H16ClF2N5O2Color and Shape:SolidMolecular weight:491.88ALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Formula:C26H29ClD3N5O3SPurity:98%Color and Shape:SolidMolecular weight:533.1UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Formula:C30H42N6O2Color and Shape:SolidMolecular weight:518.69PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92TIE-2/VEGFR-2 kinase-IN-3
CAS:<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Formula:C23H17F4N5O3SColor and Shape:SolidMolecular weight:519.47Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Formula:C32H23ClN8Purity:98.83% - 99.34%Color and Shape:SolidMolecular weight:555.03JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93BMS-935177
CAS:<p>BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.</p>Formula:C31H26N4O3Purity:99.89%Color and Shape:SolidMolecular weight:502.56Zongertinib
CAS:<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Formula:C29H29N9O2Purity:98.24%Color and Shape:SolidMolecular weight:535.6
